S-1/A: Kairos Pharma Files Amendment to Form S-1 for $6.2 Million Initial Public Offering

Clinical-stage biopharmaceutical company Kairos Pharma, Ltd. has filed an amendment to its Form S-1 registration statement with the SEC, seeking to raise $6.2 million in an initial public offering.

Summary

• Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, has filed an amendment to its Form S-1 registration statement with the SEC for a $6.2 million initial public offering.
• The company is focused on developing therapeutics for cancer patients, targeting immune suppression and drug resistance.
• Kairos Pharma's pipeline includes seven drug candidates, including antibodies and small molecules for various cancers like prostate, lung, breast, and glioblastoma.
• The company's key patents are licensed from Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc.
• The initial public offering price is expected to be $4.00 per share, with 1,550,000 shares of common stock being offered.
• The company plans to list its common stock on the NYSE American under the symbol 'KAPA'.
• The net proceeds from the offering, estimated to be approximately $5.6 million, will be used to fund Phase 1 and Phase 2 clinical trials, potential acquisitions or in-licensing activities, and for working capital and general corporate purposes.
• The company has granted the underwriters a 45-day option to purchase up to an additional 232,500 shares to cover over-allotments.
• As of September 30, 2023, Kairos Pharma reported a net loss of $0.7 million for the nine months ended and an accumulated deficit of $5.1 million since inception.

Sentiment

Score: 3

Explanation: The company is in a challenging financial position with significant losses and a need for substantial additional funding. The success of the IPO and the company's ability to advance its clinical programs are highly uncertain.

Positives

• Kairos Pharma has a diversified pipeline of seven drug candidates.
• The company has partnerships with leading medical centers like Cedars-Sinai.
• ENV 105 has shown a 62% clinical benefit rate in a previous Phase 2 trial for prostate cancer.
• The company has a strong management team with experience in drug development and commercialization.
• The IPO proceeds will provide funding for clinical trials and operations for at least the next 12 months.

Negatives

• The company has a limited operating history and has incurred significant losses since inception.
• The company has no products approved for commercial sale and has not generated any revenue.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company will require substantial additional funding to continue operations and advance its product candidates.
• The company faces substantial competition from larger, more established companies.
• The company is heavily dependent on the success of its initial drug candidates, which are still under clinical development.
• The regulatory approval process is lengthy, time-consuming, and unpredictable.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company may be unable to raise additional capital when needed, which could force delays or cessation of product development programs.
• Raising additional capital may cause dilution to existing stockholders or require relinquishing rights to technologies or product candidates.
• Clinical trials are expensive, time-consuming, and may not yield successful results.
• The company relies on third parties to conduct clinical trials and manufacture clinical trial materials, and their performance may impact development timelines and regulatory approvals.
• The market opportunities for the company's product candidates may be limited or smaller than anticipated.
• The company may face product liability lawsuits.
• The company's intellectual property rights are subject to agreements with third parties, and disputes or termination of these agreements could harm the business.
• Changes in healthcare laws and regulations could impact the company's ability to obtain approval for or commercialize its products.
• The trading price of the company's common stock may be volatile.
• The company may not be able to satisfy listing requirements of the NYSE American or maintain a listing of its common stock on such exchange.

Future Outlook

The company expects to continue to incur significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through development, seeks regulatory approval, maintains and expands its intellectual property portfolio, hires additional personnel, and operates as a public company.

Industry Context

The announcement relates to the broader trend of biopharmaceutical companies going public to raise capital for clinical development. It also highlights the competitive landscape in the oncology therapeutics market, particularly in the areas of immunotherapy and drug resistance.

Comparison to Industry Standards

• The clinical benefit rate of 62% observed in the Phase 2 trial for ENV 105 in prostate cancer compares favorably to historical response rates seen with androgen-targeted therapies alone in similar patient populations. For example, enzalutamide (Xtandi) and abiraterone (Zytiga) have demonstrated response rates in the range of 20-50% in clinical trials for castration-resistant prostate cancer.
• The company's focus on developing therapies to overcome drug resistance is in line with industry trends, as resistance to targeted therapies and immunotherapies is a major challenge in cancer treatment. Several companies are developing drugs that target resistance mechanisms, including AstraZeneca, Roche, and Novartis.
• The company's strategy of developing companion diagnostics to identify potential drug responders is also consistent with industry trends. Companies like Myriad Genetics and Foundation Medicine have developed companion diagnostics that are used to guide treatment decisions for various cancer therapies.

Corporate Governance

Related Party Transactions

• During the year ended December 31, 2021, shareholders of the Company, and a company whose principal stockholder is also a stockholder of the Company, advanced the Company $0.01 million.
• As of December 31, 2022 and September 30, 2023, a total of $0.004 million remained outstanding on these advances.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares in the offering and future capital raises. Potential for significant losses if the company is unable to successfully develop and commercialize its product candidates.
• Employees: Potential job creation and opportunities for professional development as the company expands its operations.
• Customers: Potential for new and innovative cancer therapies if the company's product candidates are successful.
• Suppliers: Potential for increased business opportunities if the company's product candidates are successful and require manufacturing and supply chain support.
• Creditors: Potential risk of non-payment if the company is unable to raise sufficient capital or generate revenue.

Next Steps

• Complete the initial public offering and list common stock on the NYSE American.
• Advance the clinical development of ENV 105 and KROS 201.
• Initiate a Phase 1 trial of activated T cell therapy for KROS 201 in patients with glioblastoma.
• Complete pre-IND studies for the checkpoint inhibitor KROS 101.
• Continue to advance the pipeline of immunotherapeutics for clinical trials.
• Seek additional funding to support operations and clinical development beyond the next 12 months.

Key Dates

Keywords

cancer therapeutics, immunotherapy, drug resistance, immune suppression, prostate cancer, lung cancer, breast cancer, glioblastoma, clinical trials, biopharmaceutical, drug development, Phase 1, Phase 2, ENV 105, KROS 201, Cedars-Sinai Medical Center, Tracon Pharmaceuticals, IPO, initial public offering, NYSE American, SEC, FDA, IND